Understanding Cibinqo and Rinvoq
Cibinqo (abrocitinib) and Rinvoq (upadacitinib) are both oral Janus kinase (JAK) inhibitors approved for treating certain types of eczema and other inflammatory conditions [1][2]. While they share a similar mechanism of action, they are distinct medications with specific approvals and characteristics.
What are Cibinqo and Rinvoq approved for?
Cibinqo is approved for adults with moderate to severe atopic dermatitis (eczema) that is not adequately controlled by topical treatments [1]. Rinvoq is approved for adults and adolescents (12 years and older) with moderate to severe atopic dermatitis, as well as for other conditions like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis [2].
How do Cibinqo and Rinvoq work?
Both Cibinqo and Rinvoq work by inhibiting specific Janus kinases (JAKs), which are enzymes involved in the signaling pathways that drive inflammation in conditions like atopic dermatitis [1][2]. By blocking these pathways, they help to reduce the symptoms of inflammation, such as itching and skin rash.
What is the difference in their dosages?
Cibinqo is typically taken once daily [1]. Rinvoq is also taken once daily but may have different dosage strengths depending on the condition being treated [2].
What are the potential side effects of these medications?
Common side effects for both Cibinqo and Rinvoq can include upper respiratory tract infections, acne, headache, and increased levels of certain liver enzymes [1][2]. More serious side effects can include increased risk of serious infections, blood clots, heart attack, stroke, and certain cancers. Patients should discuss potential risks with their healthcare provider [1][2].
How do their clinical trial results compare?
Clinical trials have demonstrated that both Cibinqo and Rinvoq are effective in improving skin clearance and reducing itch in patients with moderate to severe atopic dermatitis [1][2]. Specific efficacy rates can vary between trials and patient populations.
When do the patents for Cibinqo and Rinvoq expire?
Patent information for these medications is complex and can involve multiple patents covering different aspects of the drug. Information on patent expiry for specific JAK inhibitors can be found on resources like DrugPatentWatch.com [3]. For example, as of late 2023, patents for upadacitinib (Rinvoq) are expected to begin expiring around 2028, while abrocitinib (Cibinqo) patents are also subject to various expiry dates [3].
Are there any generic versions available or expected soon?
Currently, neither Cibinqo nor Rinvoq have generic versions available. The availability of generics depends on patent expiry and regulatory approval [3].
Who manufactures Cibinqo and Rinvoq?
Cibinqo is manufactured by Pfizer Inc. [1]. Rinvoq is also manufactured by AbbVie Inc. [2].
---
1. Cibinqo Prescribing Information
2. Rinvoq Prescribing Information
3. DrugPatentWatch.com